219 related articles for article (PubMed ID: 22333523)
21. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.
Lee BH; Kim YK; Park SH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):714-7. PubMed ID: 16571367
[TBL] [Abstract][Full Text] [Related]
22. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
[TBL] [Abstract][Full Text] [Related]
23. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
24. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
Rudman Y; Duskin-Bitan H; Richter I; Tsvetov G; Masri-Iraqi H; Akirov A; Shimon I
Andrology; 2023 Oct; 11(7):1398-1407. PubMed ID: 36897756
[TBL] [Abstract][Full Text] [Related]
25. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
26. Normalization of prolactin with aripiprazole in a patient with psychotic depression and a comorbid pituitary microadenoma.
Steinhagen CK
Psychosomatics; 2007; 48(4):350-1. PubMed ID: 17600173
[No Abstract] [Full Text] [Related]
27. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacodynamic metoclopramide (cerucal) test in differential diagnosis of hypoprolactinemic hypogonadism syndrome in women].
Balabolkin MI; Gerasimov GA; Liubimov AV
Akush Ginekol (Mosk); 1990 Feb; (2):54-7. PubMed ID: 2339765
[TBL] [Abstract][Full Text] [Related]
29. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists.
Chanson P
Best Pract Res Clin Endocrinol Metab; 2022 Dec; 36(6):101711. PubMed ID: 36280567
[TBL] [Abstract][Full Text] [Related]
30. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.
Cavallaro R; Cocchi F; Angelone SM; Lattuada E; Smeraldi E
J Clin Psychiatry; 2004 Feb; 65(2):187-90. PubMed ID: 15003071
[TBL] [Abstract][Full Text] [Related]
31. Aripiprazole for the Management of Antipsychotic-Induced Hyperprolactinemia A Retrospective Case Series.
Yeager A; Shad MU
Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999895
[TBL] [Abstract][Full Text] [Related]
32. Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report.
Casulari LA; de Castro LF; Kessler IM; Mendonça JL; de Fátima Magalhães Gonzaga M
J Med Case Rep; 2019 Jun; 13(1):183. PubMed ID: 31202268
[TBL] [Abstract][Full Text] [Related]
33. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
34. Severe exacerbation of psychosis after sudden withdrawal of chlorpromazine in the treatment of methamphetamine-associated psychosis with aripiprazole and chlorpromazine: 2 case reports.
Wang G; Devi Thakoor JP; Wang X; Hao W
J Addict Med; 2014; 8(6):479-81. PubMed ID: 25303986
[TBL] [Abstract][Full Text] [Related]
35. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
[TBL] [Abstract][Full Text] [Related]
36. Dopamine partial agonists: a new class of antipsychotic.
Lieberman JA
CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
[TBL] [Abstract][Full Text] [Related]
37. Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist.
Burke MJ; Lincoln J
Ann Clin Psychiatry; 2006; 18(2):129-30. PubMed ID: 16754419
[No Abstract] [Full Text] [Related]
38. Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature.
Kuloglu M; Ekinci O; Albayrak Y; Caykoylu A
Arch Womens Ment Health; 2010 Oct; 13(5):443-7. PubMed ID: 20179976
[TBL] [Abstract][Full Text] [Related]
39. Osteoporotic fractures in patients with untreated hyperprolactinemia vs. those taking dopamine agonists: A systematic review and meta-analysis.
D'Sylva C; Khan T; Van Uum S; Fraser LA
Neuro Endocrinol Lett; 2015; 36(8):745-9. PubMed ID: 26921574
[TBL] [Abstract][Full Text] [Related]
40. Prolactinoma-associated headache and dopamine agonist treatment.
Kallestrup MM; Kasch H; Østerby T; Nielsen E; Jensen TS; Jørgensen JO
Cephalalgia; 2014 Jun; 34(7):493-502. PubMed ID: 24351278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
